Table 2.
Univariate and multivariate analysis for the initiation of anticoagulation at discharge.
| Variable | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Non-anticoagulant group | Anticoagulant group | P value | OR | (95% CI) | P value | |
| (n =9,827) | (n = 6,335) | |||||
| Age, years, Mean ± SD | 78 ± 9 | 75 ± 10 | <0.001 | 0.973 | (0.970–0.977) | <0.001 |
| Male, n (%) | 5,061 (51.5) | 3,535 (55.8) | <0.001 | 1.014 | (0.526–1.120) | 0.786 |
| Prior medical history | ||||||
| Ischemic stroke/TIA, n (%) | 2,825 (28.7) | 1,719 (27.1) | 0.026 | 0.890 | (0.826–0.965) | 0.011 |
| Hemorrhagic stroke, n (%) | 327 (3.3) | 125 (2.0) | <0.001 | 0.647 | (0.527–0.795) | <0.001 |
| Gastrointestinal bleeding, n (%) | 187 (1.9) | 73 (1.2) | <0.001 | 0.607 | (0.463–0.804) | 0.003 |
| Urinary tract bleeding, n (%) | 3 (0) | 2 (0) | 0.971 | - | ||
| Smoking, n (%) | 2,271 (23.1) | 1,694 (26.7) | <0.001 | 1.029 | (0.760–1.471) | 0.400 |
| Anticoagulants, n (%) | 585 (6.0) | 1,173 (18.5) | <0.001 | 3.408 | (3.065–3.789) | <0.001 |
| New comorbidity during hospitalization | ||||||
| Any intracranial bleeding, n (%) | 1,112 (11.3) | 222 (3.5) | <0.001 | 0.268 | (0.232–0.309) | <0.001 |
| Gastrointestinal bleeding, n (%) | 427 (4.3) | 122 (1.9) | <0.001 | 0.353 | (0.263–0.475) | <0.001 |
| Urinary tract bleeding, n (%) | 14 (0.1) | 11 (0.2) | 0.622 | - | ||
| Pneumonia, n (%) | 3,345 (34.0) | 1,113 (17.6) | <0.001 | 0.601 | (0.553–0.652) | <0.001 |
| Hypertension, n (%) | 8,098 (82.4) | 5,222 (82.4) | 0.967 | - | ||
| Diabetes, n (%) | 1,885 (19.2) | 1,233 (19.5) | 0.658 | - | ||
| Dyslipidemia, n (%) | 3,401 (34.6) | 2,395 (37.8) | <0.001 | 1.044 | (0.910–1.112) | 0.324 |
| Coronary heart disease, n (%) | 2,030 (20.7) | 1,160 (18.3) | <0.001 | 0.942 | (0.869–1.095) | 0.258 |
| Heart failure, n (%) | 402 (4.1) | 180 (2.8) | <0.001 | 0.884 | (0.745–1.241) | 0.282 |
| Renal insufficiency, n (%) | 961 (9.8) | 498 (7.9) | <0.001 | 0.841 | (0.752–0.952) | 0.013 |
| Peripheral artery disease, n (%) | 404 (4.1) | 297 (4.7) | 0.079 | - | ||
| Anemia, n (%) | 444 (4.5) | 203 (3.2) | <0.001 | 0.823 | (0.696–1.018) | 0.062 |
| Deep vein thrombosis, n (%) | 308 (3.1) | 252 (4.0) | 0.004 | 1.711 | (1.446–2.020) | <0.001 |
| SBP, mmHg, Mean ± SD | 151 ± 24 | 148 ± 23 | <0.001 | 0.998 | (0.996–0.999) | 0.003 |
| DBP, mmHg, Mean ± SD | 85 ± 15 | 85 ± 15 | 0.98 | - | ||
| Baseline NIHSS score, Median (IQR)* | 6 (2,14) | 3 (1,7) | <0.001 | 0.943 | (0.937–0.947) | <0.001 |
| Reperfusion therapy, n (%) | 1,786 (18.2) | 1,133 (17.9) | 0.64 | - | ||
| Length of stay, days, Median (IQR) | 11 (8–15) | 11 (9–15) | <0.001 | 1.044 | (1.039–1.050) | <0.001 |
CI indicates confidence interval; DBP, diastolic blood pressure; IQR, interquartile range; NIHSS, national institutes of health stroke scale; OR, odds ratio; SD, standard deviation; SBP, systolic blood pressure; TIA, transient ischemic attack.
*
NIHSS was available for 13,766 patients (5,570 in anticoagulant group and 8,196 in non-anticoagulant group).